No Data
Peijia Medical's 2024 Loss Narrows
PEIJIA-B (09996.HK) has impressive performance in 2024: revenue increased by 39.5%, with double growth in TAVR and Medical intervention Business.
Gelonghui, March 26 – PEIJIA-B (09996.HK) announced that for the year ending December 31, 2024, the group's revenue during the reporting period was RMB 0.615 billion, an increase of 39.5% compared to 2023. The composition of revenue remained stable, with 42.2% coming from TAVR-related product sales and 57.8% from neurointerventional product sales (2023: 42.1% and 57.9% respectively). The strong revenue growth was mainly due to high sales growth in the transcatheter valve therapy and neurointerventional business. The sales revenue of TAVR-related products during the reporting period...
PEIJIA-B (09996) released its annual performance, with a loss attributable to Shareholders of 0.227 billion yuan, a year-on-year decrease of 42.28%.
PEIJIA-B (09996) announced its annual performance for the year ended December 31, 2024, with a revenue of 6.1...
Express News | Peijia Medical FY Gross Margin 70.5%
Express News | Peijia Medical FY Net Income RMB -228.5 Million
Express News | Peijia Medical FY Capex RMB 280.1 Million
Peijia Medical Limited's (HKG:9996) 29% Share Price Plunge Could Signal Some Risk
